Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Etoposide × NET × Clear all

Phase

Status

Sponsor Class

OTHER 2 OTHER_GOV 1 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3 Plasma cell 2 Other hematologic neoplasm 2 Lymphoid 2 NET 1 Gynecologic 1 Gastrointestinal 1 Endocrine 1

Conditions

Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

olaparib 1 copper dotatate CU-64 1 Tomography, Emission-Computed, Single-Photon 1 PM 01183 1 Lutetium-177 1 Irinotecan 1 Iodine-124 1 Iodine-123 1 Injections 1 Etoposide 1 Cisplatin 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03963193 2019-05-24

Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type

Henan Cancer Hospital

Phase 2 Unknown

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡